Efficacy and Safety of Lithium-Carbamazepine Combination in Mania

  • Sashi Shukla
  • Brian L. Cook


Despite the demonstrated efficacy of lithium carbonate during acute episodes of mania and as a prophylactic agent in bipolar disorders, 20–25% of patients fail to respond to this treatment.1,2 Some clinical predictors of lithium nonresponsiveness have been noted in rapid cycling disorders,3 mixed manic disorders,4 and patients with associated neuropsychiatry factors.4 Often, although there are no controlled studies, such patients are clinically treated with combinations of lithium and neuroleptics. Such patients are subject to the unpleasant side effects and potentially more harmful effects of the tardive dyskinesia5 associated with neuroleptics. In addition, a significant number of patients clinically fail to respond adequately to even this combined regimen.


Bipolar Disorder Tardive Dyskinesia Bipolar Patient Lithium Therapy Unpleasant Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stokes PE, Stoll PM, Shamoian CA, et al. Efficacy of lithium as acute treatment of manic depressive illness. Lancet 1971; 1: 1319–1325.PubMedCrossRefGoogle Scholar
  2. 2.
    Goodwin FK, Ebert MH. Lithium in mania: clinical trials and controlled studies. In Gershon S, Shopsin B (eds): Lithium: Its Role in Psychiatric Research and Treatment. New York: Plenum Press, 1973; 237–252.Google Scholar
  3. 3.
    Dunner DL, Fieve RR. Clinical factors in lithium prophylaxis failure. Arch Gen Psychiatry 1974; 30: 229–233.PubMedGoogle Scholar
  4. 4.
    Himmelhoch JM, Garfinkel ME. Sources of lithium resistance in mixed mania. Psychopharmacol Bull 1986; 22: 613–620.PubMedGoogle Scholar
  5. 5.
    Rosenbaum AH, Niven RG, Manson MP, et al. Tardive dyskinesia: relationship with a primary affective disorder. Dis Nerv Syst 1977; 38: 423–426.PubMedGoogle Scholar
  6. 6.
    Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 137: 782–790.PubMedGoogle Scholar
  7. 7.
    Post RM, Uhde TW, Ballenger JC, et al. Prophylactic efficacy of carbamazepine in manic depressive illness. Am J Psychiatry 1983; 140: 1602–1604.PubMedGoogle Scholar
  8. 8.
    Inoue K, Arima S, Tanaka K, et al. A lithium and carbamazepine combination in the treatment of bipolar disorder—a preliminary report. Folia Psychiatr Neurol Jpn 1981; 35: 465–475.PubMedGoogle Scholar
  9. 9.
    Lipinski JF, Pope HG. Possible synergistic action between carbamazepine and lithium carbonate in the treatment of three acutely manic patients. Am J Psychiary 1982; 139: 948–949.Google Scholar
  10. 10.
    Nolen WA. Carbamazepine, a possible adjunct alternative to lithium in bipolar disorder. Acta Psychiatr Scand 1983; 67: 218–225.PubMedCrossRefGoogle Scholar
  11. 11.
    Shukla S, Cook BL, Miller MG. Lithium-carbamazepine versus lithium neuroleptic prophylaxis in bipolar illness. J Affective Disord 1985; 9: 219–222.CrossRefGoogle Scholar
  12. 12.
    Shopsin D, Johnson G, Gershon S. Neurotoxicity with lithium: differential drug responsiveness. Int Pharmacopsychiatry 1970; 5: 170–182.Google Scholar
  13. 13.
    Reynolds EH. Neurotoxicity of carbamazepine. Adv Neurol 1975; 11: 345–353.PubMedGoogle Scholar
  14. 14.
    Livingston S, Pauli LL, Berman W. Carbamazepine in epilepsy: nine year follow-up study with special emphasis on untoward reactions. Dis Nerv Syst 1974; 35: 103–107.PubMedGoogle Scholar
  15. 15.
    Ghose K. Effect of carbamazepine in polyuria associated with lithium therapy. Pharmakopsychiatr Neuropsychopharmakol 1978; 11: 241–245.PubMedGoogle Scholar
  16. 16.
    Chaudhry RP, Walters BGH. Lithium and carbamazepine interaction: possible neurotoxicity. J Clin Psychiatry 1983; 44: 30–31.PubMedGoogle Scholar
  17. 17.
    Shukla S, Godwin CD, Long LEB, et al. Lithium-carbamazepine neurotoxicity and risk factors. Am J Psychiatry 1984; 141: 1604–1606.PubMedGoogle Scholar
  18. 18.
    Kutt K: Clinical pharmacology of carbamazepine in antiepileptic drugs. In Pippenger CE, Penry JK, Kutt M (eds): Quantitative Analysis and Interpretation. New York: Raven Press, 1978.Google Scholar
  19. 19.
    Kutt M, Solomon G, Wasterlain C, et al. Carbamazepine in difficult to control epileptic outpatients. Acta Neurol Scand [Suppl] 1975; 60: 27–32.CrossRefGoogle Scholar
  20. 20.
    Fogelson DL. Using carbamazepine effectively. Am J Psychiatry 1984; 141: 1130.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • Sashi Shukla
  • Brian L. Cook

There are no affiliations available

Personalised recommendations